How much funding has Avencell raised?

Avencell has raised $152.0M in total funding, most recently a Series B round.

Who are Avencell's investors?

Avencell's investors include F-Prime Capital, Japanese Agency for Medical Research and Development (AMED), Novo Holdings A/S, Eight Roads Ventures, Piper Heartland Healthcare Capital, NYBC Ventures.

Where is Avencell headquartered?

Avencell is headquartered in Watertown, Massachusetts, United States.

What industry is Avencell in?

Avencell operates in Biotech, Genomics, Therapeutics, Healthcare, Life Sciences.

Avencell

Next generation immunotherapies for hard-to-treat cancers.

Watertown, United States · Founded 2021 · $152.0M raised

Headquarters: Watertown, Massachusetts
Employees: 51–200
Founded: 2021
Business Model: B2B

Website: avencell.com
Total Funding: $152.0M
Last Round: $40.0M Series BJun 2025
Rounds: 5

About

AvenCell Therapeutics is a clinical-stage biopharma developing next-generation allogeneic and switchable CAR-T cell therapies for hard-to-treat cancers. Their proprietary platforms enable precise targeting, controllability, and safety, overcoming limitations of current immunotherapies. Backed by leading investors, they focus on advancing immunotherapies to improve patient outcomes globally.

Summary

Avencell is a Biotech company based in Watertown, United States, founded in 2021. It has raised $152.0M in total across 5 rounds, most recently a $40.0M Series B round in Jun 2025. Investors include F-Prime Capital, Japanese Agency for Medical Research and Development (AMED) and Novo Holdings A/S.

LinkedIn X (Twitter)